Literature DB >> 27520496

Update on atrial fibrillation.

Amanulla Khaji1, Peter R Kowey2.   

Abstract

Atrial fibrillation (AF) is the most common arrhythmia with a substantial effect on individual morbidity and mortality as well as healthcare expenditure. The management of AF is complex and fraught with many uncertain and contentious issues. We have seen substantial progress in AF management in the last two decades including better understanding of the epidemiology, genomics, monitoring, drug and non-pharmacological treatment of the arrhythmia, its complications and stroke risk reduction. In this review, we present a comprehensive discussion on AF with emphasis on most recent updates.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ablation; Antiarrythmic drugs; Anticoagulation; Atrial fibrillation; Stroke risk

Mesh:

Substances:

Year:  2016        PMID: 27520496     DOI: 10.1016/j.tcm.2016.06.007

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  7 in total

1.  Mechanisms by Which Ranolazine Terminates Paroxysmal but Not Persistent Atrial Fibrillation.

Authors:  Rafael J Ramirez; Yoshio Takemoto; Raphaël P Martins; David Filgueiras-Rama; Steven R Ennis; Sergey Mironov; Sandesh Bhushal; Makarand Deo; Sridharan Rajamani; Omer Berenfeld; Luiz Belardinelli; José Jalife; Sandeep V Pandit
Journal:  Circ Arrhythm Electrophysiol       Date:  2019-10-09

2.  Combinational Biomarkers for Atrial Fibrillation Derived from Atrial Appendage and Plasma Metabolomics Analysis.

Authors:  Songqing Lai; Xiumeng Hua; Ran Gao; Liang Zeng; Jiangping Song; Jichun Liu; Jing Zhang
Journal:  Sci Rep       Date:  2018-11-16       Impact factor: 4.379

3.  Circular RNA expression profiles of persistent atrial fibrillation in patients with rheumatic heart disease.

Authors:  Miaoyang Hu; Xufeng Wei; Meng Li; Ling Tao; Liping Wei; Minxia Zhang; Hexiang Cheng; Yuan Yuan
Journal:  Anatol J Cardiol       Date:  2019-01       Impact factor: 1.596

4.  Atrial fibrillation among Russian men and women aged 55 years and older: prevalence, mortality, and associations with biomarkers in a population-based study.

Authors:  Maria A Shkolnikova; Dmitri A Jdanov; Rukizhat A Ildarova; Natalia V Shcherbakova; Ekaterina B Polyakova; Evgeny N Mikhaylov; Svetlana A Shalnova; Vladimir M Shkolnikov
Journal:  J Geriatr Cardiol       Date:  2020-02       Impact factor: 3.327

5.  An Untargeted LC-MS based approach for identification of altered metabolites in blood plasma of rheumatic heart disease patients.

Authors:  Soumi Das; Yashwant Kumar; Shruti Sharma; Ruma Ray; Sudheer Arava; Sandeep Seth; Aman Agarwal; Gautam Sharma
Journal:  Sci Rep       Date:  2022-03-28       Impact factor: 4.379

6.  PU.1 inhibition attenuates atrial fibrosis and atrial fibrillation vulnerability induced by angiotensin-II by reducing TGF-β1/Smads pathway activation.

Authors:  Juan Hu; Jing-Jing Zhang; Li Li; Shan-Ling Wang; Hai-Tao Yang; Xian-Wei Fan; Lei-Ming Zhang; Guang-Ling Hu; Hai-Xia Fu; Wei-Feng Song; Li-Jie Yan; Jing-Jing Liu; Jin-Tao Wu; Bin Kong
Journal:  J Cell Mol Med       Date:  2021-06-15       Impact factor: 5.310

Review 7.  Cognitive Function and Atrial Fibrillation: From the Strength of Relationship to the Dark Side of Prevention. Is There a Contribution from Sinus Rhythm Restoration and Maintenance?

Authors:  Emanuele Gallinoro; Saverio D'Elia; Dario Prozzo; Michele Lioncino; Francesco Natale; Paolo Golino; Giovanni Cimmino
Journal:  Medicina (Kaunas)       Date:  2019-09-13       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.